Ashley Gallagher, Associate Editor

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

Laws can help eliminate common barriers to transparency but are not the only way to achieve health care transparency.

Juvéderm Voluma XC (AbbVie) is the first and only hyaluronic acid dermal filler to receive FDA approval for this indication with results lasting up to 13 months.

AAO-HNSF guideline development group included 17 panel members, including experts from otolaryngology and allergy, those who have knowledge in clinical practice guideline development, and patient representatives.

Investigators at Duke University and the University of North Carolina determine what causes recurrent UTIs, even after antibiotics cleared the bacterial infection.

Dupilumab (Dupixent; Sanofi) showed greater reductions in mucus plugs and greater improvements in airway volume and flow for individuals with uncontrolled moderate-to-severe asthma.

The FDA also granted traditional approval to amivantamab-vmjw for adults whose disease has progressed on or after platinum-based chemotherapy.

Walgreens will start dispensing the abortion pill as soon as a week.

The effects of acupuncture were independent of sex, age, medication use, and coexisting conditions, according to the results of the study published in BMJ Open.

The investigators included 24 studies across 7 countries, including Australia, Canada, New Zealand, Norway, Singapore, Sweden, and the United States.

Investigators determined that the vaccination reduced the prevalence of vaccine serotypes with an effectiveness of 89.6% based on the study results.

VK2735, a dual agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, is being developed as a potential treatment for various metabolic disorders.

NVL-520 is a novel brain-penetrant ROS1-selective TKI being investigated for ROS1-positive metastatic non–small cell lung cancer in patients who have previously been treated with 2 or more ROS1 TKIs.

If approved, epcoritamab (DuoBody CD3xCD20; AbbVie, Genmab) would be the first and only subcutaneous bispecific antibody for treatment in this patient population.

In LePage v. Center for Reproductive Medicine, the Alabama Supreme Court ruled that “extrauterine embryos” are considered children, causing some infertility clinics to halt IVF processes.

The podcast highlights addressing misinformation, the impact of celebrity endorsements in pharmaceuticals, and the important role of pharmacists in educating patients.

The data follow the FDA approval of omalizumab for the reduction of allergic reactions, including anaphylaxis, that can occur after exposure to 1 or more foods.

The results were presented as a late-breaking poster presentation at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

The new indication includes individuals with HIV who have suppressed viral loads with known or suspected M184V/I resistance.

The sNDA was based on results from the KRYSTAL-1 study, evaluating the drug alone or in combination with other anti-cancer therapies in those with advanced solid tumors who have KRASG12C mutations.

Adalimumab-ryvk is the first high-concentration, citrate-free biosimilar to Humira that has been granted interchangeability status for the 40 mg/0.4 ml injection.

As of January 2024, Keytruda has been approved for 6 indications in NSCLC across the metastatic and earlier stages of the disease.

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

This marks the first and only time that an individualized T cell therapy has been approved by the FDA for a solid tumor cancer.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

This frequency can allow for faster observation of toxicities and adherence issues.

Cardiac Solutions, a physician-owned practice specializing in personalized treatment plans, used RevUp Remote Patient Monitoring and Chronic Care Management to achieve these cardiovascular readmission rates.

If approved, this would mark the first MDMA-assisted therapy and psychedelic-assisted therapy approved, calling for a reschedule of MDMA from Schedule I. A PDUFA was set for this summer.

Bepirovirsen is a triple action investigational antisense oligonucleotide and is being evaluated in the B-Well phase 3 clinical trial program for the treatment of chronic hepatitis B.

The FDA approval marks the first and only FDA-approved oral therapy for this patient population, and the drug is expected to be available by the end of February.